Hemophagocytic Lymphohistiocytosis Clinical Trial
Official title:
An Observational, Multicenter Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
Verified date | March 2020 |
Source | NovImmune SA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This observational study is designed to provide a better understanding of the potential use of IFNγ and IFNγ-inducible chemokines as markers of HLH disease activity and prognosis, and of the potential of IFNγ as a therapeutic target in M-HLH.
Status | Completed |
Enrollment | 32 |
Est. completion date | January 29, 2020 |
Est. primary completion date | January 29, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Patients diagnosed with HLH in the context of a malignancy. The diagnosis of M-HLH will be established by the treating physician. 2. The patient or patient's legal representative (in case the patient is < 18 years old) must have consented to the use of their clinical data for research purposes at the site. 3. For the control group, patients with a diagnosis of hematological malignancy and never diagnosed with HLH or no suspicion of HLH Exclusion Criteria: N/A |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
NovImmune SA | M.D. Anderson Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Levels of Inflammatory Markers in Participants Diagnosed with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) | 6 months | ||
Primary | Relationship of Levels of Inflammatory Markers in Participants Diagnosed with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) and Disease Activity | 6 months | ||
Primary | Relationship Between Genetic Variants of Genes Causing HLH and M-HLH and Associated Inflammatory Markers | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
Recruiting |
NCT02912702 -
L-DEP as an Initial Treatment for EBV-HLH
|
Phase 3 | |
Terminated |
NCT00176826 -
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06038422 -
GTP Regimen in the Treatment of Refractory/Recurrent HLH
|
Phase 3 | |
Completed |
NCT03510650 -
Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
|
||
Active, not recruiting |
NCT01494103 -
Administration of Donor T Cells With the Caspase-9 Suicide Gene
|
Phase 1 | |
Recruiting |
NCT05164978 -
DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
|
N/A | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Terminated |
NCT01547143 -
Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
|
N/A | |
Active, not recruiting |
NCT00006056 -
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
|
N/A | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Recruiting |
NCT03795909 -
Ruxolitinib Combined With Dexamethasone for HLH
|
Phase 1/Phase 2 | |
Recruiting |
NCT03533790 -
DEP-Ru Regimen as a Salvage Therapy for HLH
|
Phase 3 | |
Not yet recruiting |
NCT05315336 -
L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
|
Phase 3 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Recruiting |
NCT04326348 -
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)
|
Phase 1 | |
Recruiting |
NCT04551131 -
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT05546060 -
Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
|
Phase 1 | |
Recruiting |
NCT05137522 -
Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
|
N/A | |
Recruiting |
NCT04120090 -
Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
|
Phase 3 |